Viyash Scientific Limited

VIYASH

INE807F01027

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:49 2026-03-17 am EDT			5-day change	1st Jan Change
191.80 ^INR	-1.64%		+0.52%	-7.85%

Feb. 13	Ruchira Papers Limited Announces Board and Committee Changes, Effective January 23 2026	CI
Feb. 06	Viyash Scientific Limited, Q3 2026 Earnings Call, Feb 06, 2026

Sequent Scientific Limited Announces Resignation of Vedprakash Ragate as Whole- Time Director (Executive Director), Effective September 30, 2025

Published on 09/10/2025 at 08:51 am EDT

S&P Capital IQ

VIYASH SCIENTIFIC LIMITED

-1.64%

Sequent Scientific Limited announced that Mr. Vedprakash Ragate, has submitted his resignation from the position of Whole- Time Director (Executive Director) of the Company, which will take effect from the close of business hours on September 30, 2025.

Latest news about Viyash Scientific Limited

Feb. 13	Ruchira Papers Limited Announces Board and Committee Changes, Effective January 23 2026	CI
Feb. 06	Viyash Scientific Limited, Q3 2026 Earnings Call, Feb 06, 2026
Feb. 06	Viyash Scientific Limited to Seek Selective Mergers and Acquisitions	CI
Feb. 05	Viyash Scientific Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025	CI
Jan. 22	Viyash Scientific partners with Boehringer Ingelheim in India	RE
Jan. 08	Sequent Scientific Limited has Changed its Name to Viyash Scientific Limited	CI
Jan. 07	Sequent Scientific Limited completed the acquisition of Viyash Life Sciences Private Limited.	CI
Dec. 23	SeQuent Scientific Limited Announces Resignation of Ashish Kakabalia as Vice President - Business Development and Formulation Designated as Senior Management Personnel, Effective December 23, 2025	CI
Dec. 16	Sequent Scientific appoints Haribabu Bodepudi as managing director and group CEO	RE
Dec. 16	Sequent Scientific Limited Announces CFO Changes, Effective January 1, 2026	CI
Dec. 16	Sequent Scientific Limited Announces Key Managerial Personnel Changes, Effective January 1, 2026	CI
Nov. 19	Sequent Scientific Limited, Q2 2026 Earnings Call, Nov 19, 2025
Nov. 14	Sequent Scientific Sept-quarter consol net profit 147.4 million rupees	RE
Nov. 14	Sequent Scientific Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025	CI
25-09-10	Sequent Scientific Limited Announces Resignation of Vedprakash Ragate as Whole- Time Director (Executive Director), Effective September 30, 2025	CI

Chart Viyash Scientific Limited

Duration

Period

VIYASH: Dynamic Chart

Company Profile

SeQuent Scientific Limited is an India-based animal health company. The Company provides a wide range of animal health products, including finished dose formulations, active pharmaceutical ingredients (APIs), as well as analytical services. The Company operates through the pharmaceuticals segment. The Company is focused on various therapies, such as targeted are anthelmintics (endo and ecto parasiticides), anti-protozoals, nutraceuticals, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-infectives and dermatology. It is specialized in analytical and bio analytical services to support the API, pharmaceutical, personal care and nutraceutical companies. It provides analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopoeia monographs, customer developed methods or in-house method development. The Companyâ€™s subsidiaries include Alivira Animal Health Limited and SeQuent Research Limited.

Employees

1,244

Sector

Pharmaceuticals

More about the company